Usage Examples
- The pre-approval inspection assessed cGMP readiness at the commercial fill-finish site.
- QA held the batch because cGMP record review found a yield deviation that was never investigated.
- Phase 1 supply is exempt from Part 211, but the statutory cGMP obligation still applies.
What is cGMP (Current Good Manufacturing Practice)?
Current Good Manufacturing Practice (cGMP) is the FDA-enforced minimum standard for the methods, facilities, and controls used to manufacture, process, pack, and hold drugs. Drugs made outside cGMP are adulterated by law, regardless of how the batch tests.
Current Good Manufacturing Practice exists because testing a finished batch cannot prove the batch is safe: a sample tells you about the sample, not about the units that ship. FDA therefore regulates the process rather than the result. Under 21 CFR 210.1(b), a drug manufactured in violation of Parts 210, 211, 225, or 226 is adulterated under section 501(a)(2)(B) of the Act, and the responsible person is subject to regulatory action.
Current Good Manufacturing Practice covers the methods, facilities, and controls used to manufacture, process, pack, and hold a drug: personnel, buildings, equipment, control of components, production and process controls, packaging and labeling, holding and distribution, laboratory controls, and records. cGMP does not reach Phase 1 investigational production, which 21 CFR 210.2(c) exempts from Part 211 while leaving the statutory obligation in 21 U.S.C. 351(a)(2)(B) fully intact.
Current Good Manufacturing Practice is applied through three things an inspector can read: a quality control unit with written authority to reject, procedures that govern each production step, and an executed record per batch that the quality control unit reviews and approves before release (21 CFR 211.192). cGMP compliance is judged on what the executed record shows, not on what the SOP says it should have shown.
Not to be confused with
- GMP
- GMP and cGMP name the same US requirements. FDA's rule text itself reads "the minimum current good manufacturing practice" (21 CFR 210.1(a)), so a supplier drawing a line between "GMP" and "cGMP" is drawing a marketing distinction, not a regulatory one.
- 21 CFR Part 211
- Part 211 is one of four parts that carry cGMP for drugs (210, 211, 225, 226 per 21 CFR 210.1(a)). cGMP is the standard; Part 211 is the specific rulebook for finished pharmaceuticals and is not the whole of cGMP.
- Quality by Design
- Quality by Design is a voluntary development approach that builds process understanding before commercial manufacture. cGMP is the mandatory floor every commercial batch must clear, and no depth of QbD work discharges a Part 211 obligation.
- Form 483
- A Form 483 records an FDA investigator's inspectional observations at a single site. cGMP is the standard being measured against; the 483 is evidence that a site missed it, not a separate requirement to comply with.
cGMP obligations attach to the manufacturer, not to the equipment or software vendor. These are the anchors.
What you must do
- 1Comply with every applicable regulation in Parts 210, 211, 225, and 226; a failure renders the drug adulterated under section 501(a)(2)(B) and makes the responsible person subject to regulatory action21 CFR 210.1(b)
- 2Establish a quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging material, labeling, and drug products21 CFR 211.22(a)
- 3Write and follow production and process control procedures designed to assure the drug products have the identity, strength, quality, and purity they purport or are represented to possess21 CFR 211.100(a)
- 4Have the quality control unit review and approve all production and control records, including packaging and labeling records, for compliance with approved written procedures before the batch is released or distributed21 CFR 211.192
- 5Apply Part 211 to investigational material once it has been made available for use in a Phase 2 or Phase 3 study, or once the drug is lawfully marketed; Phase 1 production is exempt from Part 211 but not from 21 U.S.C. 351(a)(2)(B)21 CFR 210.2(c)
Common mistakes
Treating release testing as proof of cGMP compliance
Adulteration under 21 CFR 210.1(b) follows from the failure to comply with the regulations, not from a failing assay. A batch that meets every specification is still adulterated if the process that produced it was out of compliance, and it stays exposed to recall and regulatory action after it ships.
Reading the Phase 1 exemption as a cGMP holiday
21 CFR 210.2(c) exempts Phase 1 production from Part 211 only, and the exemption lapses the moment the material is made available for a Phase 2 or Phase 3 study. Teams that kept thin records through Phase 1 end up rebuilding the process, the documentation, and the timeline at exactly the point the program is trying to accelerate.
Giving the quality control unit a signature but not the authority
21 CFR 211.22(a) grants the quality control unit authority to approve or reject, and 21 CFR 211.192 requires its review before release. When that unit reports into manufacturing or is scheduled against a shipping date, the approval exists and the control does not, and the gap shows up in the executed batch records rather than in the org chart.
When This Matters
- The pre-approval inspection assessed cGMP readiness at the commercial fill-finish site.
- QA held the batch because cGMP record review found a yield deviation that was never investigated.
- Phase 1 supply is exempt from Part 211, but the statutory cGMP obligation still applies.
Frequently Asked Questions
None that matters in US practice. FDA's own regulations are titled current good manufacturing practice, and 21 CFR 210.1(a) describes Parts 210, 211, 225 and 226 as the minimum current good manufacturing practice. Outside the US, GMP is the ordinary term for the same concept; no regulator maintains two separate standards.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- CMC Workflows
Track ICH quality guidelines automatically and get alerts when changes impact your products
- Quality/QA Workflows
Track GxP regulation changes and enforcement trends
